


Urokinase-Type Plasminogen Activator (PLAU) Antibody

Catalogue No.:abx033923



PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.

Target:	Urokinase-Type Plasminogen Activator (PLAU)
Clonality:	Polyclonal
Reactivity:	Human
Tested Applications:	ELISA, WB, IHC, IF/ICC, FCM
Host:	Rabbit



Recommended dilutions	: WB: 1/1000, IHC-P: 1/10 - 1/50, IF/ICC: 1/10 - 1/50, FCM: 1/10 - 1/50. Not tested in IHC-F. Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
lmmunogen:	KLH-conjugated synthetic peptide between 396-426 amino acids from the C-terminal region of human Urokinase (PLAU).
lsotype:	IgG
Form:	Liquid
Purification:	Purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Storage:	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
UniProt Primary AC:	P00749 (<u>UniProt</u> , <u>ExPASy</u>)
KEGG:	hsa:5328
String:	9606.ENSP00000361850
Molecular Weight:	Calculated MW: 48.5 kDa
Buffer:	PBS containing 0.09% sodium azide.
Note:	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.